Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn
- 7 June 2012
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 64 (3), 540-582
- https://doi.org/10.1124/pr.111.004770
Abstract
Prostacyclin (PGI2) is a member of the prostanoid group of eicosanoids that regulate homeostasis, hemostasis, smooth muscle function and inflammation. Prostanoids are derived from arachidonic acid by the sequential actions of phospholipase A2, cyclooxygenase (COX), and specific prostaglandin (PG) synthases. There are two major COX enzymes, COX1 and COX2, that differ in structure, tissue distribution, subcellular localization, and function. COX1 is largely constitutively expressed, whereas COX2 is induced at sites of inflammation and vascular injury. PGI2 is produced by endothelial cells and influences many cardiovascular processes. PGI2 acts mainly on the prostacyclin (IP) receptor, but because of receptor homology, PGI2 analogs such as iloprost may act on other prostanoid receptors with variable affinities. PGI2/IP interaction stimulates G protein-coupled increase in cAMP and protein kinase A, resulting in decreased [Ca2+]i, and could also cause inhibition of Rho kinase, leading to vascular smooth muscle relaxation. In addition, PGI2 intracrine signaling may target nuclear peroxisome proliferator-activated receptors and regulate gene transcription. PGI2 counteracts the vasoconstrictor and platelet aggregation effects of thromboxane A2 (TXA2), and both prostanoids create an important balance in cardiovascular homeostasis. The PGI2/TXA2 balance is particularly critical in the regulation of maternal and fetal vascular function during pregnancy and in the newborn. A decrease in PGI2/TXA2 ratio in the maternal, fetal, and neonatal circulation may contribute to preeclampsia, intrauterine growth restriction, and persistent pulmonary hypertension of the newborn (PPHN), respectively. On the other hand, increased PGI2 activity may contribute to patent ductus arteriosus (PDA) and intraventricular hemorrhage in premature newborns. These observations have raised interest in the use of COX inhibitors and PGI2 analogs in the management of pregnancy-associated and neonatal vascular disorders. The use of aspirin to decrease TXA2 synthesis has shown little benefit in preeclampsia, whereas indomethacin and ibuprofen are used effectively to close PDA in the premature newborn. PGI2 analogs have been used effectively in primary pulmonary hypertension in adults and have shown promise in PPHN. Careful examination of PGI2 metabolism and the complex interplay with other prostanoids will help design specific modulators of the PGI2-dependent pathways for the management of pregnancy-related and neonatal vascular disorders.Keywords
This publication has 293 references indexed in Scilit:
- Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)Published by Wiley ,2010
- Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic strokeAtherosclerosis, 2009
- Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiationJournal of Molecular and Cellular Cardiology, 2009
- Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemiaJournal of Neuroimmunology, 2009
- Large-scale expression, purification, and characterization of an engineered prostacyclin-synthesizing enzyme with therapeutic potentialArchives of Biochemistry and Biophysics, 2008
- The Diagnosis, Management, and Postnatal Prevention of Intraventricular Hemorrhage in the Preterm NeonateClinics in Perinatology, 2008
- Differential regulation of RhoA-mediated signaling by the TPα and TPβ isoforms of the human thromboxane A2 receptor: Independent modulation of TPα signaling by prostacyclin and nitric oxideCellular Signalling, 2008
- IP receptor-dependent activation of PPARγ by stable prostacyclin analoguesBiochemical and Biophysical Research Communications, 2007
- Antiplatelet agents for preventing pre-eclampsia and its complicationsCochrane Database of Systematic Reviews, 2007
- Prostaglandins PGE2 and PGI2 promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activationExperimental Cell Research, 2007